Interim Analysis Results of Buntanetap in Phase 3 Clinical Studies in Alzheimer’s and Parkinson’s Disease
Alzheimer's & Dementia · 2023-12 · 19 (S21)
DOI: 10.1002/alz.074275 ↗Kurz gefasst
Fachartikel in der Zeitschrift Alzheimer's & Dementia, online erschienen am 25.12.2023. Verfasst von Cheng Fang und 5 weiteren Autor:innen. Die Arbeit wurde bisher 2-mal zitiert (Crossref).
Themen: Demenz
Abstract (Originalsprache)
Background
Overexpression of neurotoxic proteins drives downstream events that dysregulate axonal transport, lead to inflammation, nerve cell death, and loss of function. By inhibiting the translation of neurotoxic aggregating proteins ‐ amyloid precursor protein, tau, alpha‐synuclein etc., buntanetap restores axonal transport, lowers inflammation, and protects nerve cells from dying. In phase 2a studies, buntanetap showed efficacy in two double‐blind, placebo controlled clinical studies in both AD and PD patients. These encouraging data support our further development of buntanetap into phase 3 as a potential treatment for both AD and PD.
Method
We started two double‐blind, placebo‐controlled phase 3 studies to further test buntanetap’s efficacy and safety in PD and AD patients.
Result
For the PD study, patients are dosed with either 10mg, 20mg buntanetap or placebo QD. A total of 450 early PD patients are being recruited for a 6‐month treatment. Primary endpoint is MDS‐UPDRS 2 and 3. We will present the study design and the data from the interim analysis, when 30% of the patients have been treated for 2 months. For the AD study, patients are dosed with three doses of buntanetap (placebo, 7.5, 15 and 30 mg QD). A total of 320 mild to moderate AD patients are being recruited for a 3‐month treatment. Primary endpoints are ADAS‐Cog11 and ADCS‐CGIC. We will present the study design and the data from the interim analysis, when 30% of the patients have been treated for 6 weeks.
Conclusion
Our phase2 data support that buntanetap is safe, well‐tolerated, and efficacious in both AD and PD population. The interim analysis will ensure we have the right sample size to test buntanetap’s efficacy in treating AD and PD.
Zitieren
APA
Fang, C., Gaines, M., Damiano, E., Nagy, A., Ng, D., & Maccecchini, M. L. (2023). Interim Analysis Results of Buntanetap in Phase 3 Clinical Studies in Alzheimer’s and Parkinson’s Disease. Alzheimer's & Dementia, 19(S21). https://doi.org/10.1002/alz.074275
Vancouver
Fang C, Gaines M, Damiano E, Nagy A, Ng D, Maccecchini ML. Interim Analysis Results of Buntanetap in Phase 3 Clinical Studies in Alzheimer’s and Parkinson’s Disease. Alzheimer's & Dementia. 2023;19(S21). doi:10.1002/alz.074275
BibTeX
@article{Fang2023,
author = {Fang, Cheng and Gaines, Melissa and Damiano, Eve and Nagy, Anne‐Marie and Ng, David and Maccecchini, Maria L.},
title = {Interim Analysis Results of Buntanetap in Phase 3 Clinical Studies in Alzheimer’s and Parkinson’s Disease},
journal = {Alzheimer's & Dementia},
year = {2023},
volume = {19},
number = {S21},
doi = {10.1002/alz.074275}
}
EUVIMED